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Most chemically induced tumors of mice express unique antigens that can be recognized by cy- 
totoxic T  lymphocytes (CTL) and thereby mediate tumor rejection. The number of different 
antigens expressed by a single tumor and their interplay during immunization and rejection are 
largely unexplored. We used CTL clones specific to individual tumor antigens to examine the 
number and distribution of CTL antigens expressed by cell lines derived from 3-methylcholan- 
threne-induced sarcomas of (C57BL/6J ￿  SPRET/Ei)F1 mice. Each tumor cell line expressed 
one or more antigens that were unique, that is, not detected on cell lines from independent sar- 
comas. Immunoselection against an immunodominant antigen produced both major histocom- 
patibility complex class I antigen and unique tumor antigen loss variants. Immunization of  mice 
with antigen-negative immunoselected variants resulted in CTL that recognized additional an- 
tigens  that were  also  expressed by the  progenitor tumor.  Some CTL recognized additional 
unique tumor antigen(s); other CTL recognized a shared antigen expressed not only by the im- 
munizing cell line, but also by independent sarcoma cell lines and untransformed myoblastoid 
cell lines.  CTL that recognized the shared antigen were also recovered from mice immunized 
in vivo with an untransformed myoblastoid cell line. These findings support a model of immu- 
nodominance among chemically induced tumor antigens in which shared antigens are masked 
by unique immunodominant antigens. 
C 
hemically induced, transplantable tumors of  mice have 
been used extensively to investigate immunologically 
mediated tumor rejection (1), and understanding the cellu- 
lar mechanisms and molecular antigens responsible for tu- 
mor rejection in such mouse models may enable the devel- 
opment  of more  effective  immunotherapies.  Historically, 
studies  have  used  in  vivo tumor rejection assays to  indi- 
rectly investigate antigens expressed by 3-methylcholanthrene 
(MCA)l-induced tumors.  These studies demonstrated that 
immunization  with  a  chemically  induced  tumor  usually 
protects against in vivo challenge by the same tumor, but 
only rarely or sporadically protects against  challenge by in- 
dependent syngeneic tumors (2-4). These observations led 
to the suggestion that the antigens responsible for mediating 
antitumor immunity to MCA-induced  tumors are unique 
to individual tumors. 
More recently, CD8 + CTL have been shown to be nec- 
essary for immunity to transplantable  sarcomas  (5, 6),  and 
1Abbreviations used in this paper: CML, cell-mediated  lympholysis; MCA, 
3-methylcholanthrene;  MLTC, mixed lymphocyte  tumor culture. 
the antigens recognized by tumor-specific CTL have come 
under investigation. Short-term CTL lines from immunized 
mice have been used to demonstrate that the CTL antigens 
of MCA-induced  sarcomas  consist  of MHC  class I-bound 
peptides on the cell surface (7). Each peptide antigen is ex- 
pressed only by a single sarcoma,  correlating with the pattern 
of in vivo protection. The unique CTL antigens expressed 
by MCA-induced mouse tumors contrast with the CTL anti- 
gens of human melanomas, which are lineage-specific (8, 9) 
or "activation" (10) antigens expressed by multiple tumors. 
The contribution of single  antigens  to  tumor rejection 
has  been investigated in mouse models using in vitro im- 
munoselection  to  generate  CTL-resistant  tumor  variants 
that lack expression of the selected antigen. For some highly 
immunogenic tumors, including spontaneously regressing, 
UV-induced sarcomas and SV-40 large T  antigen-induced 
sarcomas,  multiple epitopes independently mediate rejection 
(11-14).  For other UV-induced and some chemically in- 
duced tumors, selected loss of an individual antigen produces 
variants that display a more malignant phenotype than their 
antigen-expressing progenitor  tumors  (15-17),  indicating 
that the selected antigen is the principal target of tumor re- 
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spectrum  of antigens that  are  available as  targets,  and im- 
munoselection provides  a  powerful  tool for  exposing sec- 
ondary epitopes to evaluation. 
The use of monoclonal CTL to study antigenic diversity 
of MCA-induced  tumors  has  been limited.  In this report, 
we use CTL lines and clones to investigate the antigens ex- 
pressed by cell lines derived from MCA-induced sarcomas 
of highly heterozygous,  (C57BL/6J  ￿  SPRET/Ei)F1, termed 
(B6  ￿  SPE)F/  mice.  The  antigenic complexity of one tu- 
mor  cell  line  was  investigated by  selecting  CTL-resistant 
variants in vitro and characterizing the immune response to 
the variants. CTL with new specificities were derived, iden- 
tifying previously undetected antigens. Some variant-reac- 
tive CTL lines defined one or more uniquely expressed an- 
tigen(s);  other  CTL  lines defined  a  shared  antigen whose 
expression  could  not be  inferred  from  the  CTL  response 
against primary cell lines. 
Materials  and Methods 
Tumor Cell Lines.  The  tumors and their derivative cell lines 
exanfined in this study have been previously described in detail 
(18).  Briefly, cell lines were  derived from MCA-induced sarco- 
mas generated in male and female mice from an F 1 cross between 
C57BL/6J (B6) and SPRET/Ei (SPE).  All tumor lines were diag- 
nosed  histologically as  poorly  differentiated  sarcomas  or  rhab- 
domyosarcomas that grew progressively and could be transplanted 
into syngeneic hosts. Cell lines derived from tumors were grown 
in  100-mm  tissue  culture-treated  petri  plates  (Coming  Glass 
Works, Coming, NY) in DMEM-based Vc medium (18) supple- 
mented with 5% FCS (Hyclone Laboratories, Inc., Logan, UT). 
Cell  lines were  passaged  weekly by preparation of a  single-cell 
suspension using trypsin-EDTA (Sigma Chemical Co., St. Louis, 
MO)  and vigorous pipetting and reseeding fresh plates.  For im- 
nmnization and T  cell-mediated lympholysis (CML) assays, cells 
were harvested from petri plates and washed twice in PBS before 
use. The male-derived tumor cell lines used in this study were bs2 
and its clonal derivative, bs2.1; bs4 and its clone, bs4.1; and bs15 
and  its  clone,  bs15.1;  and  the  female-derived tumor  cell  lines 
were  bs9 and its  clone, bsg.1.  The  NK-sensitive Yac-I  cell line 
was passaged weekly in Vc5 medium. 
U, tran.fomwd Myoblastoid  Cell Lira's.  Untransformed  myoblasts 
were  derived  from  (B6  X  SPE)F 1 neonates.  Muscle  tissue  was 
carefully  dissected  from  skin,  bone,  and  fat,  minced  into  fine 
pieces,  and rocked for  1 h  at 37~  in 10 ml of HBSS  (GIBCO 
BILL,  Gaithersburg, MD)  containing 1  mg/ml  collagenase and 
2.5 U/ml hyaluronidase (Sigma). Large pieces of tissue were al- 
lowed to  settle out,  then suspended cells  were  washed twice in 
PBS  (GIBCO BRL)  and plated in Vcl0 medium in a  100-mm 
tissue  culture-treated  cell  culture  dish  (Coming).  Myoblastoid 
cells  were  passed  weekly into fresh  Vcl0  (same  formulation as 
Vc5, except with 10% FCS) at a 1-10 dilution. 
Mouse lmmlmizations.  (B6  X  SPE)F 1 mice  (same  sex  as im- 
munizing tumor) were inmmnized by intraperitoneal injection of 
3-5  ￿  10  ~' irradiated  (1,000  Gy) tumor cells  admixed with  150 
~g  heat-killed  Corynebacterium  pawum  (19;  culture  kindly pro- 
vided  by  Dr.  C.  Cummins, Virginia Polytechnical Institute and 
State  University, Blacksburg, VA). Immunized mice were boosted 
at weekly intervals two or three times with 3 ￿  10 ~' irradiated tu- 
mor cells without C.  parvum.  10 d to 2 wk after the final boost, 
animals were euthanized by carbon dioxide asphyxiation, spleens 
were  removed,  and mononuclear splenocyte preparations  were 
obtained. Mice for these  experiments were  bred and housed at 
The Jackson Laboratory Research Animal Facility following pro- 
tocols approved by the institutional Animal Care and Use Com- 
mittee and conforming to the American Association for Accredi- 
tation of Laboratory Animal Care (AAALAC) standards. 
Mixed  Lymphocyte~Tumor  Cultures  (MLTC)  and  CTL  Lines. 
Primary MLTC  were  generated by in vitro culture of 2  ￿  107 
mononuclear splenocytes, 2  ￿  10  a irradiated  (l,500  Gy)  tumor 
cells, 6 ml Vcl0 media, and 25 U/ml IL-2 (a generous gift of M. 
Widmer, Immunex Corp., Seattle, WA). After 3 d ofm vitro cul- 
ture, MLTC were  expanded  1:3  into Vcl0 with 25  U/ml IL-2. 
MLTC were passaged  weekly thereafter in 16-ram tissue culture 
wells (Costar Corp., Cambridge, MA) by restimulation of 1-3 ￿ 
1115 MLTC cells,  5  ￿  10  ~ irradiated (200 Gy) syngeneic spleno- 
cytes,  1-3 ￿  l0  s irradiated (1,000 Gy) tumor cells, and 25 U/ml 
IL-2 in Vc  medium supplemented with 5-10% fetal bovine se- 
rum.  Some MLTC  were  supplemented with  1:20 volume anti- 
CD4 ascites fluid (clone GK1.5) during the third and fourth pas- 
sages to block antigen-specific CD4 + cell proliferation. After five 
or six passages in vitro, MLTC usually exhibited consistent growth 
characteristics from week to week, and were considered to be sta- 
ble CTL lines. CTL clones were  derived from established CTL 
lines by micromanipulation of single cells as previously described 
(20).  For  restimulation before  CML  assays, MLTC  and  CTL 
were  passaged  as  described above,  but with 30-40  U/ml  IL-2; 
and cell supernatants were  replaced 24 h  before assay with fresh 
Vc5 supplemented with 5 U/ml IL-2. 
The (B6 ￿  SPE)F I CTL lines used in this study (and their cog- 
nate tumor lines, used for immunization and restimulation) were 
BxS/2  (bs2),  BxS/4  (bs4)  BxS/9  (bsg),  BxS/15  (bs151, BxS/V 
(15V.1),  and BxS/A (15A11. The (B6  ￿  SPE)FI CTL clones used 
(and  their  cognate  tumor  lines)  were  BxS/15.4  (bs15.1);  and 
BxS/A.11  (15A1). The SPE CTL line S/4 (H2K  b restricted) and 
the B6 CTL clone B/4.4 (H2  spF" restricted) were restinmlated us- 
ing tmnor lines bs4 or bs4.1 
Immunoselection.  Variant tumors lines were  obtained by two 
different immunoselection procedures that involved slight varia- 
tions  on  previously  described  protocols  (21,  22).  The  variant 
15V.1  cell  line was  cloned by  micromanipulation from  a  bulk 
population of variant cells derived from the bsl5 tumor cell line 
that  survived multiple rounds of selection with  the  CTL  clone 
BXS/15.4.  The  variant  t5A1  cell line was  obtained as  1 of 13 
growth positive wells out of 384 total wells that were seeded with 
bs15.1  tumor cells  and subjected to multiple rounds of selection 
with the CTL clone BXS/15.4. 
Flow Cytometry.  FACS  |  (Becton Dickinson &  Co.,  Moun- 
tain View, CA) was performed at The Jackson  Laboratory Flow 
Cytometry  Facility with  a  FACScan  |  fluorocytometer  (Becton 
Dickinson). Dead cells were  excluded by propidium iodine gat- 
ing, and relative fluorescence (expressed in arbitrary units) of flu- 
orescein- or rhodamine-conjugated mAbs was determined. The 
mAbs that were  used included 28-13-3  (K  b) and 28-14-8  (1)b), 
neither of which stains H2  see MHC alleles (not shown); YTS169 
(CDS); GKI.5 (CD4); and H57-597 (ci/[B TCR). 
CML Assay.  4-6-h  CML  assays were  performed  as  previ- 
ously described (23).  51Cr released into the supernatant was deter- 
mined, and specific lysis was calculated using the following ratio: 
specific lysis  =  (experimental  -  spontaneous) / (maximum  -- st~ontam'ol~s  ) 
Data  are  reported  as  the  mean  of three  wells.  SDs  (generally 
<5%) are omitted for clarity of presentation. The ability of vari- 
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tion of 1/20 vol antibody ascites to microplate wells. In some ex- 
periments, tumor target cells were  grown in 5  U/ml IFN-y (a 
generous gift from Dr. van der Meide, Biomedical Primate P,,e- 
search Center, Rijswijk, The Netherlands) for 48 h before assay to 
augment surface expression of MHC class I molecules. T cell lym- 
phoblast target cells were cultured from splenocytes in Vc5 supple- 
mented with 25U/ml IL-2 and 2  I~g/ml Con A  (Sigma).  These 
cells were used as CML targets 2-5 d later. 
Results 
(B6  ￿  SPE)F  I  Tumors Express Unique Tumor Antigens. 
Tumor  cells lines were  used  to  immunize  (B6  ￿  SPE)F1 
mice, and  CTL  lines were  derived from  inmaunized sple- 
nocytes by in vitro restimulation. Fig. 1 shows CML assays 
using  CTL  lines established from  four mice,  each  immu- 
nized with a  different tumor cell line. Each  CTL  demon- 
strated specific lysis of its cognate tumor cell line, and failed 
to  show  significant lysis of independent  tumor  cell lines, 
untransformed  syngeneic  cell  lines,  or  Yac-1  cells.  CTL 
clones  exhibiting identical specificity as  the  bulk  cultures 
have been obtained for each CTL line. These CML results 
are representative of multiple experiments for each tumor, 
and  they  indicate  that  CTL  derived by  these  techniques 
from mice immunized with (B6  ￿  SPE)F 1 sarcomas recog- 
nize exclusively unique antigens. 
Antigen expression in the cloned, bs15.1  tumor cell line 
was characterized further. A CD8 +, Ix/J3 TCR + CTL clone, 
BxS/15.4, which specifically lysed a clonal derivative of its 
cognate tumor cell line, bs15.1, was isolated (Fig. 1).  Lysis 
was inhibited by anti-CD8 MAb and anti-H2K  b mAb, but 
not  by  anti-CD4  mAb  or  anti-H2D  b  mAb  (not  shown). 
These  data indicate that tumor cell line bs15.1  expresses a 
tumor-specific, Kb-restricted CTL antigen. 
CTL-resistant  Tumor  Variants  Express Different Pheno- 
types.  To further investigate antigen expression by bs15.1 
tumor cells, CTL-resistant variants were isolated by immu- 
noselection with CTL clone BxS/15.4.  Variant 15V.1  was 
isolated by micromanipulation of a single cell from a popu- 
lation of CTL-resistant cells. Variant cell line 15A1 was iso- 
lated in an independent, microwell-based immunoselection, 
and based on the Poisson distribution is highly likely to be 
clonally derived. Variants  15V.1  and  15A1  were examined 
by  flow  cytometry for  MHC  antigen  expression,  and  by 
CML  assay for sensitivity to various CTL  (Fig. 2).  Tumor 
variant line  15V.1  expressed  H2D  b  (not  shown),  but  not 
H2K  b, when  analyzed by flow cytometry. Cell line 15V. 1 
retained  sensitivity to  the  H2SPE-restricted  CTL,  B/4.4, 
indicating that  15V.1  was  capable  of presenting  endoge- 
nous antigens; however,  15V.1  was resistant to Kb-restricted 
CTL S/4, as well as the CTL BXS/15.4.  These results indi- 
cate that variant  15V.1  acquired resistance to the selecting 
CTL  (BXS/15.4)  because of lack of H2K  b cell-surface ex- 
pression.  In  contrast,  variant  15A1  cells  expressed  both 
H2K  b and H2D b (not shown) by FACS  |  analysis, and they 
retained  sensitivity  to  both  CTL  B/4.4  and  CTL  S/4. 
These results indicate that variant 15A1  acquired resistance 
to the selecting CTL through loss of the tumor-specific an- 
tigen recognized by CTL BXS/15.4. 
CTL  Generated to Antigen-loss  Variants of bs15.1  Define 
Additional bs15.1 Antigens.  To examine the antigenic com- 
plexity of tumor cell line bs15.1, CTL lines with additional 
antigenic specificities were  generated  (Fig. 3).  Splenocytes 
from a mouse immunized with variant line 15V. 1  (lacking 
H2K  b)  were  restimulated  with  irradiated  15V.1  cells  to 
generate a CD8 +, c~/[3 TCP, + CTL line BxS/V. The  (un- 
cloned) CTL BxS/V lysed all tumor cell lines derived from 
tumor  bsl5,  including  the  immunizing  tumor  15V.1,  its 
progenitor tumor bs15.1, and the unique antigen loss vari- 
ant 15A1. However, CTL BxS/V did not lyse Yac-1  cells, 
independently  derived sarcoma  cell lines  including bs4.1, 
or  untransformed  syngeneic  myoblastoid cells.  Thus,  the 
antigen recognized by BxS/V  was  unique  to  the bsl5  tu- 
mor,  but  not restricted by H2K  b,  and not identical to the 
bs15.1  epitope recognized by CTL BXS/15.4. 
In  contrast,  the  CD8 +,  cx/[3  TCR +  CTL  BxS/A,  de- 
rived from splenocytes of a mouse immunized with variant 
cell line  15A1,  detected an  antigen with  an  unexpectedly 
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BxS/15.4  Figure  1.  Long-term  antitu- 
mor CTL lines lyse their cognate 
tumor. Each graph represents the 
results ofa CML assay  using a sin- 
gle, independently derived CTL 
versus its cognate tumor and five 
other targets. The CTL line is in- 
dicated above each graph, and the 
number in the CTL name corre- 
sponds  to  the  number  of the 
cognate, uncloned tumor against 
which  the  CTL  was  derived. 
BXS/15.4 is a cloned CTL  line 
"~"  derived from BxS/15. Targets for 
each  assay included  indepen- 
i  ~  dently derived sarcoma cell lines 
1  10  bs2  (-rig--),  bs4  (--5<-),  bs9 
(-4b-),  bs15 (-I--),  untrans- 
formed  syngeneic  myobla~ts 
(--~), and Yac-I cells (+). Each symbol represents the mean of three replicate wells. The SD (cognate tumor only) is indicated by a vertical bar 
or is smaller than the plot symbol. 
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Figure 2.  CML assays (top  graphs) and FACS  | 
analysis (bottom graphs) reveal that  immunose- 
lected variants express different phenotypes.  (a) 
Progenitor  tumor clone bs15.1 is lysed by the 
selecting  CTL  BXS/15.4 (-{~-),  allo-H2 svE- 
specific CTL  clone  13/4.4 (-O-),  and  allo- 
H2Kb~pecific CTL line, S/4 (-~-), Flow cy- 
tometric analysis shows expression of H2K  I' by 
bs15.1. (b) lmmunoselected variant 15V. 1 is ly- 
sed by B/4.4,  but not by BXS/15.4 or S/4 (leg- 
end key same as in a). Flow cytometric analysis 
demonstrates  lack of expression  of H2K  b by 
15V.1 cells. (c) Immunoselected variant 15At is 
not lysed by BxS/15.4,  but is lysed by B/4.4 
and S/4 (legend key same as in a). Flow cyto- 
metric  analysis demonstrates  expression  by 
15A1 ofH2K  b. 
broad expression pattern. This CTL line lysed cell lines bs 15.1, 
15V.1,  and  15A1,  but  not  Yac-1  cells  or  untransformed 
Con A-stimulated T  cell blasts. Additionally, CTL BxS/A 
lysed independently derived tumor clones bs2.1, bs4.1, and 
bs9.1,  as well as untransformed syngeneic myoblasts, indi- 
cating that BxS/A recognized an antigen expressed in com- 
mon  among  multiple  independent  sarcoma  cell  lines.  A 
CTL clone, BxS/A.11,  was derived from the BxS/A  CTL 
line and demonstrated identical target specificity (Fig. 3). The 
failure  of BxS/A  to  lyse  Con  A-stimulated splenic  T  cell 
blasts, LPS-stimulated splenic B  cell blasts (not shown),  or 
Yac-1 cells indicated that the antigen is not expressed as an ar- 
tifact of in vitro cell growth, and is not expressed by cells of 
the lymphoid lineage. Moreover,  trypsin-EDTA treatment 
of splenic  T  cell blasts  did  not  sensitize  them  to  lysis  by 
BxS/A. 11, while cell cultures freshly prepared ex vivo from 
progressing bs15.1  tumors retained sensitivity (not shown), 
indicating that  cell  preparation  or  culture  conditions  are 
unlikely to account for the observed cross-reactive antigen. 
Shared Ant(~ens Are Weak Elicitors of CTL.  To  test  the 
relative  efficacy  of different  antigens to  elicit  CTL,  addi- 
tional MLTC  were derived and tested for lyric activity. Six 
unimmunized (B6  ￿  SPE)FI mice were examined. MLTC 
derived from all unimmunized mice did not proliferate well 
upon restimulation, and they failed to demonstrate lyric ac- 
tivity against any target  tested  (e.g.,  8/A,  Fig.  4).  The  in- 
ability to derive tumor-reactive MLTC  from naive (unim- 
munized) mice indicates the requirement for in vivo printing 
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i~  ￿84  u  m 
60 
40 
2o]  
1  10  1  10  1  10  1  10 
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Figure 3.  CTL lines derived against immunose- 
lected variants recognize additional antigens. Each 
graph represents the results of a CML assay with a 
single CTL and multiple targets. CTL lines are in- 
dicated above each graph. Target cell lines are rep- 
resented  thus: bsl5.1  (-I"-) and its variant lines 
15V.1 (-C]-) and 15A1 (  []]  ); independently de- 
rived syngeneic MCA tumor ceil lines bs2.1 (4i-), 
bs4.1 (--~), and bs9.1 (~);  untransformed syn- 
geneic  myoblasts (--0--)  and  syngeneic  splenic 
blasts (-K)-); and Yac-I  cells (+). 
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Figure  4.  After four passages in vitro, 
some MLTC lyse bsl 5.1-derived tumors 
when tested in a CML assay. Mice  1-3 
were  immunized  with  tumor  cell  line 
15A1;  mouse  8  was  not  immunized. 
Splenocytes from each mouse were re- 
stimulated  with  tumor cell  line  15A1. 
MLTC line  1/A from mouse 1 and 8/A 
from mouse 8  display  no  sarcoma-spe- 
cific  lysis; MLTC  2/A  from  mouse  2 
and MLTC line 3/A from mouse 3 ex- 
press  lytic  activity  against  secondary 
unique antigens.  Targets:  tumor bs15.1 
(-~),  variant  15V.1  (-~),  variant 
15A1  ([]),  independently  derived 
sarcoma  bs4.1  (-X-),  untransformed 
syngeneic myoblasts (-q~-), and Yac-1 
cells (+). 
to generate CTL with the antigen specificities  exhibited by 
lines BXS/15.4, BxS/V, and BxS/A.11. 
Four additional mice were immunized, and their spleno- 
cytes were restimulated in vitro using tumor cell line bs15.1. 
All four MLTC specifically lysed the cognate tumor, bs15.1, 
but failed to lyse the tumor antigen-specific variant, 15A1 
(not shown), indicating that the CTL populations in these 
additional MLTCs recognize the same unique tumor anti- 
gen as CTL BXS/15.4. The H2Kb-restricted bs15.1  antigen 
recognized by all these  CTLs is therefore immunodomi- 
nant, in that it is highly effective at eliciting CTL under the 
culture conditions used. 
Three additional MLTC were established  from spleno- 
cytes of mice immunized with tumor cell line 15A1 and re- 
stimulated with 15A1 cells (Fig.  4).  MLTC 2/A  and 3/A 
demonstrated potent specific  lysis of bsl5.1  cells and vari- 
ants 15V.1 and 15A1, but not of tumor cell line bs4.1 or un- 
transformed myoblasts. This pattern of reactivity is identical 
to that exhibited by the CTL line BxS/V, and indicates rec- 
ognition of a secondary tumor-specific  antigen(s). MLTC 1/A 
demonstrated relatively high lysis of Yac-1 targets, indicat- 
ing NK-like or LAK-like nonspecific cytotoxicity, but lit- 
de  additional sarcoma-specific lyric activity.  MLTC  2/A 
and 3/A also initially demonstrated low levels oflysis of sar- 
coma bs4.1  and untransformed myoblastoid lines (replicate 
experiments, not shown). This lytic activity could indicate 
a minor population of CTL that recognized a shared anti- 
gen with the same specificity as the BxS/A line. 
Immunization  with Untransformed Myoblasts Primes against a 
Shared Tumor Antigen.  Four mice were immunized with un- 
transformed myoblasts. Splenocytes from these mice were 
split,  and one  half was  restimulated using untransformed 
myoblasts while the other half was restimulated using tu- 
mor cell line 15A1. All MLTC derived by restimulating in 
vitro using myoblasts failed to lyse any target tested. How- 
ever, three of the four MLTC from myoblast-immunized 
splenocytes  that  were  restimulated  with  tumor  cell  line 
15A1 demonstrated target cell lysis. All three MLTC ex- 
hibited lysis of bs 15.1, bs4.1,  and untransformed myoblasts, 
but not of Yac-1 cells or splenic T cell blasts. One example 
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of a pair of MLTCs derived from splenocytes of a single 
mouse, but restimulated using two different antigen sources, 
is shown in Fig. 5. The antigen specificity exhibited by the 
MLTC  from  myoblast-immunized,  tumor-restimulated 
MLTC  recapitulates  the  target  specificity  exhibited  by 
CTL BxS/A. 
Discussion 
Despite the widespread use of MCA tumors for investi- 
gating immunological tumor rejection  (1,  17),  the use of 
monoclonal CTL lines  to probe tumor antigen expression 
has been limited. The results  presented here demonstrate 
that CTL lines and clones derived from (B6 ￿  SPE)F1 mice 
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Figure  5.  Development of shared antigen-specific  lytic  activity  from 
immunized splenocytes in MLTC depends on the source of antigen used 
for  in  vitro  restimulation.  Splenocytes  from  representative,  myoblast- 
immunized mouse 4 were divided into two aliquots;  one was restimulated 
with myoblasts (4/myo), while the other was restimulated with tumor cell 
line 15A1 (4/A). MLTC 4/myo fails to generate lyric activity  against any 
target  tested,  while MLTC 4/A lyses the same array of targets as the BxS/ 
A CTL line.  Legend key is the same as the one in Fig. 4. immunized and restimulated with syngeneic MCA-induced 
sarcoma cell lines exhibit specific lysis of their cognate (im- 
munizing)  tumor cell lines. Lysis of independent  tumor cell 
lines  was  not  observed,  indicating  that  the  primary  CTL 
antigens expressed by MCA-induced sarcomas are uniquely 
expressed  by individual  tumors.  These  results  recapitulate 
and  extend  the  extensively  replicated  observation  that 
chemically  induced  and  W-induced  sarcomas are  inunu- 
nogenic, but fail to elicit cross-protective immunity (7, 24). 
The  genetic  mechanisms  by  which  tumor  cells  escape 
CTL lysis can be studied by applying an in vitro CTL im- 
munoselection  approach.  We observed that selective pres- 
sure on the highly heterozygous tumor cell line bs15.1  re- 
sulted  in  both  MHC  antigen  variants  and  unique  tumor 
antigen  variants.  It is interesting  that these  variant pheno- 
types reflect mutational  alterations  also observed in human 
and  mouse  tumors  in  vivo  (25-27),  suggesting  that  CTL 
selective pressure  can shape tumor progression in patients. 
Because (B6  X  SPE)F 1 tumor cell lines comprise abundant 
polymorphism between B6 and SPE alleles throughout  the 
genome, they should expedite genetic analysis of mutations 
accompanying antigen loss after immunoselection  and pro- 
vide a powerful tool for understanding  genetic mechanisms 
of tumor progression. 
To  investigate  the  antigenic  complexity  of tumor  cell 
line  bs15.1,  variants  lacking  expression  of  the  immun- 
odominant  antigen  were  exploited for detecting additional 
CTL antigens.  Two  qualitatively different, secondary anti- 
gens of tumor bs15.1  elicit CTL.  A  secondary  tumor-spe- 
cific  antigen  is recognized  by CTL BxS/V.  Expression  of 
multiple tumor-specific antigens by a single tumor has been 
previously reported,  including  UV-induced  sarcomas with 
highly immunogenic "regressor" phenotypes (11, 17). Expres- 
sion of multiple  tumor-specific  antigens by MCA-induced 
tumors  is  therefore  not  unexpected,  although  it  has  not 
been extensively reported.  More surprising is the  observa- 
tion that a shared antigen  recognized by CTL BxS/A.11  is 
expressed by independent  MCA-induced  sarcomas as well 
as  untransformed  myoblastoid  cell  lines.  Shared  antigens 
were  unexpected  under  these  experimental  circumstances 
because  no  cross-reactive  lytic  activity  was  generated  in 
bulk  MLTCs  against  the  progenitor  bs15.1  cell  line,  and 
shared antigens of UV-induced  and MCA-induced  tumors 
are not routinely  observed using in vitro approaches  or in 
vivo cross-protection assays. 
The  three  CTL  antigens  expressed  by  tumor  cell  line 
bs15.1  exhibit a gradation ofimmunodonfinance  under the 
experimental conditions  used to generate MLTC.  The pri- 
mary  tumor-specific  antigen  monopolized  the  CTL  re- 
sponse when it was expressed by the immunizing/restimu- 
lating  tumor.  Most  MLTC  generated  by  using  primary 
antigen-loss  variants  15A1  and  15V.1  recognized  the  tu- 
mor-specific secondary  antigen,  although  one MLTC  rec- 
ognized  the  shared  antigen.  Finally,  although  the  shared 
antigen  appears  to  be  the  weakest  of  the  three  CTL- 
defined  antigens,  under  appropriate  conditions,  the  shared 
antigen-specific  CTL  activity  was  reproducibly  generated. 
The  failure  to  observe  persistent  lytic  activity  aimed  at 
more than a single antigen suggests that these activities may 
be mutually  exclusive.  Thus,  these  results support  the  hy- 
pothesis  that  immunodominant,  tumor-specific  antigens  of 
MCA-induced  tumors  not  only provoke  a  strong,  tumor- 
specific CTL response, but they may also suppress or mask 
responses  against weaker antigens,  including  both  second- 
ary tumor-specific antigens and shared antigens. 
The  coexpression  of immunodominant  tumor-specific 
antigens  and  secondary,  shared  antigens  may explain  spo- 
radic reports of in vivo cross-protection in immunized ani- 
mals. While most studies investigating in vivo rejection in- 
dicate that cross-protection between MCA sarcomas is rare 
(3,  4,  28),  sporadic  cases  of  cross-protection  have  been 
reported: Basombrio  (4)  demonstrated  replicable cross-pro- 
tection with one combination out of 14 MCA-induced  tu- 
mors,  and  Prehn  and  Main  (2)  showed  significant  cross- 
protection  in  two  of the  four  tumor  combinations  they 
tested.  This  rare  in  vivo  cross-protection  may reflect  spo- 
radic priming against a shared sarcoma antigen  in the  con- 
text  of frequent  priming  against  unique  antigens.  Further 
studies  are needed  to characterize  the nature  of the shared 
antigen  detected  on  (B6  ￿  SPE)F~  sarcomas and to evalu- 
ate  the  efficacy of shared-antigen  specific  CTL  for tumor 
rejection  in  vivo.  The  use  of untransformed  myoblastoid 
cell lines to prime  a  CTL response  against shared  antigens 
offers a new tool to dissect the potential role of shared anti- 
gens in tumor rejection. 
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